Lupin and Avas Launch NaMuscla® in Italy for Myotonia Treatment

Lupin Limited has joined forces with Avas Pharmaceuticals SRL to bring NaMuscla® (mexiletine) to Italy, marking a milestone in treating non-dystrophic myotonic (NDM) disorders. NaMuscla® is the first and only licensed medication for myotonia in adults, addressing a significant unmet need in neuromuscular care. By reducing myotonia symptoms, the drug enhances patient quality of life and functional outcomes. While Lupin negotiates reimbursement with the Italian Medicines Agency (AIFA), Avas will commercialize the drug under the current classification to ensure accessibility for Italian patients.

Thierry Volle, President EMEA at Lupin, emphasized the company’s commitment to rare disease treatment, while Marco Rago, President of Avas Pharmaceuticals, highlighted the partnership’s role in improving patient outcomes. This launch extends NaMuscla®’s availability across key European markets, including Germany, France, Spain, Austria, Norway, Sweden, and the UK, reinforcing Lupin’s mission to enhance rare disease treatment options worldwide.